Literature DB >> 35713627

NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification.

Danielle C Costigan1,2, Marisa R Nucci1, Brendan C Dickson3, Martin C Chang4, Sharon Song1,5, Lynette M Sholl6, Jason L Hornick6, Christopher D M Fletcher6, David L Kolin1.   

Abstract

NTRK -rearranged uterine sarcomas are rare spindle cell neoplasms that typically arise in the uterine cervix of young women. Some tumors recur or metastasize, but features which predict behavior have not been identified to date. Distinguishing these tumors from morphologic mimics is significant because patients with advanced stage disease may be treated with TRK inhibitors. Herein, we present 15 cases of NTRK- rearranged uterine sarcomas, the largest series to date. Median patient age was 35 years (range: 16 to 61). The majority arose in the uterine cervix (n=14) and all but 2 were organ-confined at diagnosis. Tumors were composed of an infiltrative, fascicular proliferation of spindle cells and most showed mild-to-moderate cytologic atypia. All were pan-TRK positive by immunohistochemistry (13/13); S100 (11/13) and CD34 (6/10) were usually positive. RNA or DNA sequencing found NTRK1 (10/13) and NTRK3 (3/13) fusions with partners TPR , TPM3 , EML4 , TFG , SPECC1L , C16orf72 , and IRF2BP2 . Unusual morphology was seen in 2 tumors which were originally diagnosed as unclassifiable uterine sarcomas, 1 of which also harbored TP53 mutations. Follow up was available for 9 patients, of whom 3 died of disease. By incorporating outcome data of previously reported tumors, adverse prognostic features were identified, including a mitotic index ≥8 per 10 high-power fields, lymphovascular invasion, necrosis, and NTRK3 fusion. Patients with tumors which lacked any of these 4 features had an excellent prognosis. This study expands the morphologic spectrum of NTRK -rearranged uterine sarcomas and identifies features which can be used for risk stratification.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35713627      PMCID: PMC9481736          DOI: 10.1097/PAS.0000000000001929

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  39 in total

1.  Institutional implementation of clinical tumor profiling on an unselected cancer population.

Authors:  Lynette M Sholl; Khanh Do; Priyanka Shivdasani; Ethan Cerami; Adrian M Dubuc; Frank C Kuo; Elizabeth P Garcia; Yonghui Jia; Phani Davineni; Ryan P Abo; Trevor J Pugh; Paul van Hummelen; Aaron R Thorner; Matthew Ducar; Alice H Berger; Mizuki Nishino; Katherine A Janeway; Alanna Church; Marian Harris; Lauren L Ritterhouse; Joshua D Campbell; Vanesa Rojas-Rudilla; Azra H Ligon; Shakti Ramkissoon; James M Cleary; Ursula Matulonis; Geoffrey R Oxnard; Richard Chao; Vanessa Tassell; James Christensen; William C Hahn; Philip W Kantoff; David J Kwiatkowski; Bruce E Johnson; Matthew Meyerson; Levi A Garraway; Geoffrey I Shapiro; Barrett J Rollins; Neal I Lindeman; Laura E MacConaill
Journal:  JCI Insight       Date:  2016-11-17

2.  Endocervical fibroblastic malignant peripheral nerve sheath tumor (neurofibrosarcoma): report of a novel entity possibly related to endocervical CD34 fibrocytes.

Authors:  Anne M Mills; Jason R Karamchandani; Hannes Vogel; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2011-03       Impact factor: 6.394

3.  Molecular characterization of cancers with NTRK gene fusions.

Authors:  Zoran Gatalica; Joanne Xiu; Jeffrey Swensen; Semir Vranic
Journal:  Mod Pathol       Date:  2018-08-31       Impact factor: 7.842

4.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications.

Authors:  Xiaoyu Chen; Ole Schulz-Trieglaff; Richard Shaw; Bret Barnes; Felix Schlesinger; Morten Källberg; Anthony J Cox; Semyon Kruglyak; Christopher T Saunders
Journal:  Bioinformatics       Date:  2015-12-08       Impact factor: 6.937

5.  NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum.

Authors:  Anjelica Hodgson; Cherry Pun; Bojana Djordjevic; Gulisa Turashvili
Journal:  Int J Gynecol Pathol       Date:  2021-01       Impact factor: 2.762

Review 6.  Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.

Authors:  Christian Rolfo; Rossana Ruiz; Elisa Giovannetti; Ignacio Gil-Bazo; Antonio Russo; Francesco Passiglia; Marco Giallombardo; Marc Peeters; Luis Raez
Journal:  Expert Opin Investig Drugs       Date:  2015-10-12       Impact factor: 6.206

7.  COL1A1-PDGFB fusion uterine fibrosarcoma: A case report with treatment implication.

Authors:  Samuel L Grindstaff; Jessica DiSilvestro; Katrine Hansen; Paul DiSilvestro; C James Sung; M Ruhul Quddus
Journal:  Gynecol Oncol Rep       Date:  2019-12-15

8.  NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Authors:  Sarah Chiang; Paolo Cotzia; David M Hyman; Alexander Drilon; William D Tap; Lei Zhang; Jaclyn F Hechtman; Denise Frosina; Achim A Jungbluth; Rajmohan Murali; Kay J Park; Robert A Soslow; Esther Oliva; A John Iafrate; Ryma Benayed; Marc Ladanyi; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.298

9.  Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.

Authors:  Akimasa Takahashi; Manabu Kurosawa; Mao Uemura; Jun Kitazawa; Yoshihiko Hayashi
Journal:  J Int Med Res       Date:  2018-06-14       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.